Business

Skyepharma revenues were up 25% in 2013, the company said, in large part due to increased sales of its Flutiform fluticasone/formoterol MDI. The company also announced that it will seek to raise £112 million through a firm placing and a placing and open offer of over 58,680,000 ordinary shares at a price of 191 pence. Skyepharma CEO Peter Grant commented, "2013 … [Read more...] about Skyepharma revenues up on increased Flutiform sales, looks to raise £112 million

NanoBio has announced that Merck has acquired exclusive rights to NanoBio's NanoStat nanoemulsion adjuvant for an intranasal respiratory syncytial virus (RSV) vaccine. Merck also acquired non-exclusive rights to the adjuvant for use in an intranasal flu vaccine. The amount of the deal, which includes an upfront payment, milestone payments, and royalties on any sales … [Read more...] about Merck licenses adjuvant technology from NanoBio for intranasal RSV vaccine

Non-profit R&D organization Southwest Research Institute (SwRI) has announced that it has received a 28-month contract extension worth $8.3 million from the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) for continued development of an intranasal isoamyl nitrite formulation for the treatment of cyanide … [Read more...] about BARDA awards $8.3 million to SwRI for intranasal isoamyl nitrite development

Vectura has announced that under a license agreement with "the US division of a leading international pharmaceutical company" signed in 2011, it has reached a milestone associated with the US development of its VR315 salmeterol/fluticasone DPI (known as AirFluSal Forspiro in Europe). According to the company, it received a payment of $10 million in August 2011 and … [Read more...] about Vectura gets additional milestone payment for development of VR315 in the US

According to a report in the Wall Street Journal, a court in Cologne, Germany has issued a preliminary injunction preventing Sandoz from marketing its AirFluSal Forspiro in Germany. GlaxoSmithKline had argued that Sandoz's salmeterol/fluticasone DPI presented unfair competition to GSK's Advair because the purple color of the Forspiro inhaler would lead consumers to … [Read more...] about GSK gets preliminary injunction preventing sales of AirFluSal Forspiro in Germany

According to Mylan, the United States District Court for the Northern District of West Virginia has upheld the validity of all of its patents related to Perforomist formoterol fumarate inhalation solution. The company says that the ruling will prevent the FDA from approving Teva's ANDA for its formoterol fumarate inhalation solution before expiration of patents … [Read more...] about US district court upholds validity of Mylan Perforomist patents

According to St. Renatus, Blue Ocean Holdings is investing an additional $5 million in the company. The funds will go toward completion of St. Renatus's New Drug Application (NDA) for its nasal mist dental anesthesia and for commercialization. St. Renatus says that it plans to submit the NDA in 2014. In February 2014, St. Renatus announced that it had completed … [Read more...] about St. Renatus gets $5 million additional funding for nasal dental anesthetic

Alexza Pharmaceuticals has announced that its European partner Ferrer has launched Adasuve loxapine inhalation powder for the treatment of agitation in schizophrenic or bipolar patients in Romania. Ferrer has a distribution agreement with Galenica for distribution in that country. In the US, Teva launched the product earlier this month. Alexza President and CEO … [Read more...] about Adasuve launched in Romania

Vectura has announced that it will acquire Activaero for a total of €130 million ($181 million). The company cited both Activaero's nebulizer technology and its pipeline of respiratory drugs as part of the rationale for the acquisition, saying that the deal "extends Vectura's technology platform into smart nebulizer-based technology, broadening Vectura's therapeutic … [Read more...] about Vectura acquires Activaero for €130 million

According to Hi-Tech Pharmacal, sales of its fluticasone propionate nasal spray dropped from $23 million in the 3rd quarter of the 2013 fiscal year to only $10.9 million for the same period in 2014. The decrease was a combination of lower unit sales and a lower average price, the company said. Sales of a homeopathic OTC nasal spray called Sinus Buster marketed by … [Read more...] about Hi-Tech Pharmacal reports large drop in nasal spray sales